Cell and gene therapies have been all the rage for some of the pharmaceutical industry’s biggest players despite a wealth of manufacturing hiccups along the way. To capture that enthusiasm, a WuXi AppTec CDMO has expanded its offerings––and it’s appointed as its head a Celgene veteran very familiar with those manufacturing woes.
WuXi AppTec has named David Chang, Ph.D., a veteran of Celgene’s CAR-T manufacturing team, to lead its cell and gene therapy-focused CDMO, WuXi Advanced Therapies, the company said Monday.
Chang most recently worked as corporate vice president and head of cell therapy global manufacturing at Celgene––which was acquired by Bristol Myers Squibb in late 2019––where he oversaw the company’s CAR-T production network, WuXi said.
Sponsored by Lubrizol Life Science
[Webinar] Cannabinoid Formulation – from Farm to Pharma
Wednesday, June 24, 2020 | 12pm ET / 9am PT
A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.
One of those CAR-T offerings, Bristol’s ide-cel (bb2121), was sent back to the drawing board in May after the FDA refused to review its submission based on slim manufacturing details in its filing.
Before Celgene, Chang was employed as global head of engineering and strategy at Roche after a turn as VP and site head for Roche Shanghai Technical Operations.
“WuXi (Advanced Therapies) is at the forefront of accelerating the development of life-saving advanced therapies with even greater quality, efficiency and speed, and I look forward to further enhancing our cell and gene therapy R&D and manufacturing platform,” Chang said in a release.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.